摘要
目的:确定是否(1)血浆淀粉样蛋白β之间存在一种关系(Aβ)1 - 40和1-42肽水平,老年人与非遗忘型轻度认知功能损害的脑容积和认知能力(aMCI),(2)血浆Aβ肽水平在不同载脂蛋白E(APOE)ε4携带者和非携带者和(3)纵向变化的认知和大脑体积与Aβ水平相关。方法:伴随aMCI 的受试者(n = 89)与正常认知(N = 126)分别来自Sydney记忆和老龄化研究(Sydney MAS),以非痴呆人群70-90岁的为基础个体研究;39位阿尔茨海默氏病(AD)患者从专业诊所被招募。Sydney MAS参与者接受脑部核磁共振成像扫描,并被19种认知措施评估和ApoE基因ε4。等离子体水平的Aβ1-40使用ELISA和1-42量化。结果:Aβ多肽的WAVE1的血浆水平和 Aβ1−42/1-40比率在AD和aMCI 中比例较低,并且Aβ1−42与全球认知及海马体积呈负相关的白质高信号呈负相关。一个 Aβ1-40和 Aβ1-42的关系主要是分别观察ε4等位基因携带者和非携带者。纵向分析显示在全球认知和记忆更大的跌幅对Aβ1−42的最高昆泰和比率测量。结论:血浆β水平和一个 Aβ1−42 / 1比是认知及海马体积有关,与一个 Aβ1-40和 Aβ1-42在ε4携带者和非携带者微分关系。这些数据支持AD病理学Aβ模型,并表明等离子体Aβ措施可以作为生物标志物。
关键词: Aβ1-40、 Aβ1-42、APOE、脑体积、认知、神经心理学测试、MRI、血浆、白质高信号。
Current Alzheimer Research
Title:The Relationship Between Plasma Aβ Levels, Cognitive Function and Brain Volumetrics: Sydney Memory and Ageing Study
Volume: 13 Issue: 3
Author(s): Anne Poljak, John D. Crawford, George A. Smythe, Henry Brodaty, Melissa J. Slavin, Nicole A. Kochan, Julian N. Trollor, Wei Wen and Karen A. Mather, Amelia A. Assareh, Pek C. Ng, Perminder S. Sachdev
Affiliation:
关键词: Aβ1-40、 Aβ1-42、APOE、脑体积、认知、神经心理学测试、MRI、血浆、白质高信号。
摘要: Objectives: Determine whether (1) a relationship exists between plasma amyloid-β (Aβ)1- 40 and 1-42 peptide levels, brain volumetrics and cognitive performance in elderly individuals with and without amnestic mild cognitive impairment (aMCI), (2) plasma Aβ peptide levels differ between apolipoprotein E (APOE) ε4 carriers and non-carriers and (3) longitudinal changes in cognition and brain volume relate to Aβ levels. Methods: Subjects with aMCI (n = 89) and normal cognition (n = 126) were drawn from the Sydney Memory and Aging Study (Sydney MAS), a population based study of non-demented 70-90 year old individuals; 39 Alzheimer’s disease (AD) patients were recruited from a specialty clinic. Sydney MAS participants underwent brain MRI scans and were assessed on 19 cognitive measures and were APOE ε4 genotyped. Plasma levels of Aβ1-40 and 1-42 were quantified using ELISA. Results: Wave1 plasma levels of Aβ peptides and Aβ1−42/1-40 ratio were lower in aMCI and AD, and Aβ1−42 was positively associated with global cognition and hippocampal volume and negatively with white matter hyperintensities. The relationships of Aβ1-40 and Aβ1-42 were predominantly observed in ε4 allele carriers and non-carriers respectively. Longitudinal analysis revealed greater decline in global cognition and memory for the highest quintiles of Aβ1−42 and the ratio measure. Conclusion: Plasma Aβ levels and the Aβ1−42/1-40 ratio are related to cognition and hippocampal volumes, with differential associations of Aβ1-40 and Aβ1-42 in ε4 carriers and non-carriers. These data support the Aβ sink model of AD pathology, and suggest that plasma Aβ measures may serve as biomarkers of AD.
Export Options
About this article
Cite this article as:
Anne Poljak, John D. Crawford, George A. Smythe, Henry Brodaty, Melissa J. Slavin, Nicole A. Kochan, Julian N. Trollor, Wei Wen and Karen A. Mather, Amelia A. Assareh, Pek C. Ng, Perminder S. Sachdev , The Relationship Between Plasma Aβ Levels, Cognitive Function and Brain Volumetrics: Sydney Memory and Ageing Study, Current Alzheimer Research 2016; 13 (3) . https://dx.doi.org/10.2174/1567205013666151218150202
DOI https://dx.doi.org/10.2174/1567205013666151218150202 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Comprehensive Analysis of Unique and Recurrent Copy Number Variations in Alzheimer’s Disease and its Related Disorders
Current Alzheimer Research Mental Training for Cognitive Improvement in Elderly People: What have We Learned from Clinical and Neurophysiologic Studies?
Current Alzheimer Research Targeting PPARalpha in Alzheimer's Disease
Current Alzheimer Research GABAA Receptor Subtype Selective Cognition Enhancers
Current Drug Targets - CNS & Neurological Disorders A Commentary on Neuronal Degeneration and Cell Death in Guam ALS and PD: An Evolutionary Process of Understanding
Current Alzheimer Research Novel Pyrimidine based Semicarbazones: Confirmation of Four Binding Site Pharmacophoric Model Hypothesis for Antiepileptic Activity
Central Nervous System Agents in Medicinal Chemistry Brain Structural Effects of Antidepressant Treatment in Major Depression
Current Neuropharmacology Selective Elevation of Circulating CCL2/MCP1 Levels in Patients with Longstanding Post-vaccinal Macrophagic Myofasciitis and ASIA
Current Medicinal Chemistry Up-regulation of DMN Connectivity in Mild Cognitive Impairment Via Network-based Cognitive Training
Current Alzheimer Research Diabetes, Cognitive Function, and the Blood-Brain Barrier
Current Pharmaceutical Design Cardiovascular Pharmacogenetics of Anti-Thrombotic Agents and Non-Steroidal Anti-Inflammatory Drugs
Current Molecular Medicine Neuropsychiatric Disturbances in Alzheimer’s Disease: What Have We Learned from Neuropathological Studies?
Current Alzheimer Research Current Challenges to Overcome in the Management of Type 2 Diabetes Mellitus and Associated Neurological Disorders
CNS & Neurological Disorders - Drug Targets Efficient Synthesis and Discovery of Schiff Bases as Potent Cholinesterase Inhibitors
Medicinal Chemistry Amyloid-β Aggregation Inhibitory and Neuroprotective Effects of Xanthohumol and its Derivatives for Alzheimer’s Diseases
Current Alzheimer Research Modulation of the Immune System for the Treatment of Glaucoma
Current Neuropharmacology Translating Genetic Findings into Therapy in Parkinson Disease
Recent Patents on CNS Drug Discovery (Discontinued) The Neuroprotective Role of Vesicular Monoamine Transporter 2 in Neurodegenerative Diseases
Medicinal Chemistry Targeting Parkinson’s - Tyrosine Hydroxylase and Oxidative Stress as Points of Interventions
CNS & Neurological Disorders - Drug Targets The Role of Microglial Cells on Neuroinflammation: Possible Therapeutic Applications
Recent Patents on Regenerative Medicine